By Reporter 吳典叡 / Comprehensive Report
- [NEWS] MoneyDJ理財網 : Pharmasaga to List on Emerging Stock Market on 27th; Type 2 Diabetes Phase Ib Clinical Trial Aims for Completion Next Year
- [NEWS] 富聯網 : Unlisted Stocks: Pharmasaga to List on Emerging Stock Market on 27th at NT$120 Reference Price; New Type 2 Diabetes Drug to Announce Phase Ib Data in H1 Next Year
- [NEWS] 富聯網 : (Unlisted Stocks) Pharmasaga to List on Emerging Stock Market on 27th at NT$120, Will Accelerate New Drug Development
- [NEWS] 旺得富 : Pharmasaga to List on Emerging Stock Market on 27th at Reference Price of NT$120
- [NEWS] 旺得富 : (Unlisted Stocks) Pharmasaga to List on Emerging Stock Market on 27th at NT$120, Will Accelerate New Drug Development
- [NEWS] 時報資訊 : (Unlisted Stocks) Pharmasaga to List on Emerging Stock Market on 27th at NT$120, Will Accelerate New Drug Development
- [NEWS] 財訊快報 : Unlisted Stocks: Pharmasaga to List on Emerging Stock Market on 27th at NT$120 Reference Price; New Type 2 Diabetes Drug to Announce Phase Ib Data in H1 Next Year
- [NEWS] GENE ONLINE: Pharmasaga Wins Bronze Medal for Innovative Technology at the 2025 Taipei Biotech Awards
- [NEWS] NTTC: NSTC Leads 8 Biomedical Startups into BIO USA 2025; Pharmasaga Advances to Global Competition Finals Again
- [NEWS] 環球生技 : Pharmasaga's Innovative Diabetes Drug PS1 Demonstrates Curative Potential, Initiates Taiwan-US Clinical Trials
- [NEWS] 經濟部 : BIO 2025 North America Biotech Exhibition Opens; Taiwan Pavilion Showcases Taiwan's Innovative Biomedical Technology
- [NEWS] GENE ONLINE : Taiwan Participates in BIO 2025 North America Biotech Exhibition with Dual Focus on All-Age Healthcare Layout and International Connections
- [NEWS] 環球生技 : NSTC Leads 8 Biomedical Startups to BIO 2025; Pharmasaga Reaches Finals Again
- [NEWS] Yahoo新聞 : Taiwan Pavilion Showcases Taiwan's Biomedical Technology at North America Biotech Exhibition
- [NEWS] Yahoo股市 : BIO 2025 North America Biotech Exhibition: Taiwan Pavilion Highlights 5 Biomedical Innovations
- [NEWS] Ltvnews : Entering BIO USA 2025: NSTC Leads 8 Biomedical Startups; Pharmasaga Advances to Finals Again
- [NEWS] Biomedical Technology Development
- [NEWS] 工商時報 : (Industry) Taiwanese Companies Attend BIO 2025 North America Biotech Exhibition; Ministry of Economic Affairs Reveals 5 Highlights
- [NEWS] CENS : NSTC Leads 8 Biomedical Startups to BIO Exhibition in the US, Aiming for International Licensing and Investment
- [NEWS] GOTHE : Entering BIO USA 2025: NSTC Leads 8 Biomedical Startups; Pharmasaga Advances to Finals Again
The US BIO International Convention is a major global event on the global biotechnology and pharmaceutical sector calendar, bringing together top pharmaceutical companies, biotech startups, and investors from around the world. The convention offers extensive opportunities for business collaboration, particularly in licensing, technology transfer,...
Pharmasaga officially initiated its Phase I clinical trial in December 2023, following dual approval from the Taiwan Food and Drug Administration (TFDA) and the U.S. Food and Drug Administration (USFDA).
On October 18th, 2023, at the Demo Day hosted by Honsun Precision Industry Co., Ltd. and H. Spectrum+, Pharmasaga, represented by CEO Ivan Chen, stood out from 183 submissions. The Company was selected as a strategic partner for Honsun Precision's expansion into the pharmaceutical sector.
!!! HAPPENING TODAY !!! The grandest biotech exhibition in Asia, BIO Asia 2022, has officially commenced on July 28th! We have already welcomed many distinguished guests to Pharmasaga's booth.
The Ministry of Science and Technology (MoST) led 14 top-tier Taiwanese biomedical startups to the BIO International Convention (US BIO), held in San Diego, USA, from June 13th to 16th. On the 15th, the MoST's Department of Industry-Academia Collaboration hosted a local Smart Health Demo Day to facilitate networking and matching...
Health Medical News/Reporter 林怡亭, Friday, June 10, 2022, 9:00 AM
By Keoni Everington, Taiwan News, Staff Writer2021/09/23 18:33
Diabetes has remained incurable for two millennia, primarily because patients lose the number and function of their pancreatic beta-cells during the disease progression. Consequently, diabetic patients are often forced to rely on insulin injections for survival.